GC Wealth Management RIA LLC Reduces Stake in Bristol Myers Squibb Company $BMY

Key Points

• GC Wealth Management RIA LLC cut its stake in Bristol Myers Squibb by 92.7% in Q4, selling 99,204 shares and retaining 7,799 shares valued at $421,000.
• Bristol Myers Squibb beat Q1 estimates with $1.58 EPS and $11.49B revenue, and management reiterated FY‑2026 guidance (EPS 6.05–6.35) while citing growth drugs and cost cuts as margin drivers.
• Analysts remain mixed—consensus rating is Hold with a $61.31 price target—and investors face risks from the Eliquis patent cliff despite pipeline catalysts and a 4.3% dividend yield.

GC Wealth Management RIA LLC decreased its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 92.7% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 7,799 shares of the biopharmaceutical company's stock after selling 99,204 shares during the period. GC Wealth Management RIA LLC's holdings in Bristol Myers Squibb were worth $421,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of Bristol Myers Squibb by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company's stock valued at $10,719,376,000 after acquiring an additional 2,743,759 shares in the last quarter. State Street Corp raised its holdings in shares of Bristol Myers Squibb by 2.0% in the 3rd quarter. State Street Corp now owns 96,595,232 shares of the biopharmaceutical company's stock valued at $4,356,445,000 after acquiring an additional 1,855,238 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Bristol Myers Squibb by 11.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 18,143,672 shares of the biopharmaceutical company's stock valued at $818,105,000 after acquiring an additional 1,873,618 shares in the last quarter. Legal & General Group Plc raised its holdings in shares of Bristol Myers Squibb by 8.4% in the 3rd quarter. Legal & General Group Plc now owns 17,075,743 shares of the biopharmaceutical company's stock valued at $770,116,000 after acquiring an additional 1,317,199 shares in the last quarter. Finally, Pzena Investment Management LLC raised its holdings in shares of Bristol Myers Squibb by 0.4% in the 3rd quarter. Pzena Investment Management LLC now owns 14,901,604 shares of the biopharmaceutical company's stock valued at $672,062,000 after acquiring an additional 58,129 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company's stock.

Bristol Myers Squibb Stock Performance

Shares of NYSE BMY opened at $58.24 on Friday. The stock has a market cap of $118.92 billion, a price-to-earnings ratio of 16.88, a P/E/G ratio of 0.17 and a beta of 0.26. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $62.89. The stock's 50-day moving average is $59.56 and its 200 day moving average is $54.48.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating analysts' consensus estimates of $1.42 by $0.16. The company had revenue of $11.49 billion for the quarter, compared to analysts' expectations of $10.93 billion. Bristol Myers Squibb had a return on equity of 66.57% and a net margin of 15.01%.Bristol Myers Squibb's revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period last year, the firm posted $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.27 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, May 1st. Investors of record on Thursday, April 2nd were issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.3%. The ex-dividend date of this dividend was Thursday, April 2nd. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 73.04%.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: BMY posted a Q1 beat — $1.58 EPS vs. consensus ~$1.42 and $11.49B revenue — driven by growth drugs and Eliquis outperformance, which supports near‑term cash flow. Bristol Myers posts higher-than-expected quarterly profit on blood thinner, cancer sales
• Positive Sentiment: Management reiterated FY outlook and emphasized the “growth portfolio” (Breyanzi, Camzyos) and cost‑cutting progress as drivers of durable margin improvement. Bristol-Myers Squibb Signals Confident Path After Q1 Call
• Positive Sentiment: Pipeline catalysts could lift long‑term growth: Phase III readouts for milvexian (potential Eliquis successor) and Cobenfy (schizophrenia) are highlighted as multi‑year drivers. BMS brings the buzz around late-stage readouts amid a so-so Q1
• Neutral Sentiment: Analysts’ consensus price target sits near $61.31, indicating limited upside from current levels absent new positive catalysts. Bristol Myers Squibb Company NYSE: BMY Receives $61.31 Consensus PT from Analysts
• Negative Sentiment: FY 2026 guidance (EPS 6.05–6.35; revenue $46.0–47.5B) left the revenue midpoint slightly below the Street, tempering upside after the quarter and contributing to profit‑taking. Bristol Myers Squibb Reports First Quarter Financial Results for 2026
• Negative Sentiment: Analysts/coverage notes emphasize the scale of the Eliquis patent cliff (multi‑billion dollar risk over coming years), which pressures valuation beyond near‑term beats. Thinning revenues: inside the $14bn Eliquis patent cliff
• Negative Sentiment: Bernstein maintained a Hold rating, signaling that some investors and analysts want clearer evidence that growth and pipeline will offset legacy declines. Bernstein Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)

Analyst Ratings Changes

Several analysts have weighed in on BMY shares. Wells Fargo & Company reaffirmed an "outperform" rating and issued a $60.00 price target (up from $55.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Guggenheim reaffirmed a "buy" rating and issued a $72.00 price target on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Royal Bank Of Canada started coverage on Bristol Myers Squibb in a report on Tuesday, February 24th. They issued a "sector perform" rating and a $60.00 price target on the stock. Wall Street Zen raised Bristol Myers Squibb from a "buy" rating to a "strong-buy" rating in a report on Sunday, April 19th. Finally, Weiss Ratings reaffirmed a "hold (c)" rating on shares of Bristol Myers Squibb in a report on Monday, March 23rd. Eight equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Bristol Myers Squibb has a consensus rating of "Hold" and a consensus price target of $61.31.

Insider Buying and Selling at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 30,000 shares of the firm's stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the transaction, the executive vice president directly owned 159,248 shares of the company's stock, valued at approximately $9,820,824.16. This trade represents a 15.85% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.05% of the company's stock.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.